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ABSTRACT
Presbyopia is the age- related loss of near- distance 
focusing ability. The aim of this study was to identify 
patient- reported outcome measures (PROMs) used in 
clinical trials and quality- of- life studies conducted in 
individuals with presbyopia and to assess their suitability 
for use in individuals with phakic presbyopia. Literature 
searches were performed in Medline and Embase up 
until October 2017. Specific search terms were used 
to identify presbyopia studies that included a PROM. 
All clinical trials with PROM- supported endpoints in 
presbyopia were identified on  ClinicalTrials. gov. Further 
searches were conducted to retrieve articles documenting 
the development and psychometric evaluation of the 
PROMs identified. A total of 703 records were identified; 
120 were selected for full- text review. Twenty- one 
clinical trials employed PROMs to support a primary or 
secondary endpoint. In total, 13 PROMs were identified; 
a further 23 publications pertaining to the development 
and validation of these measures were retrieved. Most 
PROMs were developed prior to release of the Food and 
Drug Administration (FDA) 2009 patient- reported outcome 
guidance and did not satisfy regulatory standards. The 
Near Activity Visual Questionnaire (NAVQ) was identified as 
the most appropriate for assessing near- vision functioning 
in presbyopia. While the NAVQ was developed in line with 
the FDA guidance, the items do not reflect changes in 
technology that have occurred since the questionnaire 
was developed in 2008 (eg, the increase in smartphone 
use), and the measure was not validated in a purely phakic 
presbyopia sample. Further research is ongoing to refine 
the NAVQ to support trial endpoints related to changes in 
near- vision functioning associated with phakic presbyopia.
BACKGROUND
Presbyopia is a common age- related vision 
disorder characterised by a progressive 
inability to focus on near objects. Presbyopia 
is hypothesised to be caused by either a weak-
ening of the ciliary muscles or a loss of lens 
elasticity preventing focal point change, the 
latter considered the primary causative mech-
anism. This condition is found to occur both 
in individuals with intact natural crystalline 
lens (phakic presbyopia), as well as those who 
have undergone an invasive surgical proce-
dure involving the extraction of the natural 
crystalline lens (pseudophakic presbyopia).1–4 
It was estimated there were 1.3 billion people 
living with presbyopia worldwide in 2017, 
which is projected to increase to 1.8 billion by 
2050.5 The lens of the human eye is usually 
able to change shape in order to focus light 
onto the retina, enabling individuals to see 
objects at both near and far distances. The lens 
decreases in flexibility throughout life until, 
after the age of 40 years, it cannot change 
shape easily, leading to difficulty focusing on 
near- distance objects and performing near- 
vision activities, such as reading or threading 
a needle.1 There are currently no approved 
therapies that reverse the normal ageing 
process that causes presbyopia; instead, 
current management focuses on either 
optical correction with medical devices (eg, 
spectacles, contact lenses) or surgical inter-
vention (eg, corneal inlay, corneal refractive 
procedures and intraocular lens (IOL) 
replacement).6 Until recently, the assessment 
of treatment outcomes in both clinical trials 
and clinical practice has primarily relied on 
clinician- reported biomedical parameters, 
mostly based on Snellen or logarithm of 
the minimum angle of resolution (logMAR) 
acuity testing. However, there is now an 
increasing emphasis from regulators and 
other relevant stakeholders on the incorpo-
ration of patient voice in clinical trials.7 One 
way to include patient perspective when eval-
uating treatment efficacy is through inclusion 
of a patient- reported outcome measure 
(PROM)- supported endpoint.8–10
A patient- reported outcome (PRO) is a 
health outcome reported directly by the 
patient (ie, study participant) about the status 
of the patient’s health without amendment or 
interpretation of the patient’s response by a 
clinician or anyone else.11 In 2009, the US Food 
and Drug Administration (FDA) released 
their influential ‘Guidance for Industry 
on Patient- Reported Outcome Measures’, 
which describes the review and evaluation 
criteria for PROs used to support claims in 
approved medical product labelling.12 The 
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European Medicines Agency also published a reflec-
tion paper in 2005 to provide broad recommendations 
on health- related quality- of- life (HRQoL) evaluation 
in the context of clinical trials.13 Aside from having the 
potential to support regulatory evaluation, marketing 
authorisation and product label claims, the data gener-
ated by PROM- supported endpoints can also be of value 
for reimbursement authorities, clinicians and patients to 
quantify the added benefit of a treatment.
In order for PROM data to support an FDA product 
label claim, the PROM must assess relevant and important 
concept(s) of interest and has been developed and 
validated to the standards specified in regulator guide-
lines (including evidence of both content validity and 
psychometric validity in the population of interest) and 
included in a well- designed and adequately controlled 
clinical trial. Hence, the review and critical evaluation of 
existing PROMs have become an important first step in 
identifying a PROM that assesses the concept of interest 
(the ‘thing’ being measured; ie, near- vision functioning) 
in a defined context of use (ie, as a clinical trial endpoint 
in a sample of adults with presbyopia with intact natural 
crystalline lens or phakic presbyopes). The objective of 
the current literature review was to identify the most 
commonly cited PROMs designed for use in presbyopia 
or similar conditions and critically evaluate the evidence 
of content validity and psychometric properties, and 
as such their adequacy for use to support endpoints in 
a Novartis’s pivotal trial testing a new pharmacological 
therapy for phakic individuals with presbyopia.
METHODS
Patient and public involvement
As this is a review of the available literature on PROMs 
used in presbyopia, patients were not involved in this 
research project.
Phase 1 (search strategy and screening)
A comprehensive review of bibliographic databases 
and other sources ( ClinicalTrials. gov, Patient- Reported 
Outcome and Quality of Life Instruments Database 
(PROQOLID)) was conducted to identify PROMs that 
have been used in individuals with presbyopia. Litera-
ture searches were performed in Medline, Embase and 
Evidence- Based Medicine Reviews (Cochrane Database of 
Systematic Reviews and Database of Abstracts of Reviews 
of Effects) via Ovid SP up until October 2017 (when 
the search was conducted) using specific search strings 
(table 1). Limits were placed on searches to exclude 
articles in languages other than English or studies not 
conducted in human subjects.
Conference abstracts, case studies and case reports 
were not considered for further screening. Studies of 
populations not exclusively comprising individuals with 
presbyopia were excluded, as were studies that did not 
include a PROM. Studies assessing treatment satisfaction 
in patients with presbyopia using a non- standardised 
measure, such as a single- item visual analogue scale 
or a numeric analogue scale, were excluded. PROMs 
designed to assess only dry eye symptoms as a result of the 
use of contact lens in individuals with presbyopia were 
also excluded from further analysis.
The first- level screening was performed based on the 
title and abstract of the citations, and full- text copies 
of the studies with individuals with presbyopia were 
obtained for the next round of review, which involved 
critical full- text appraisal based on the aforementioned 
criteria.
Phase 2 (evaluation of PROMs)
In order to assess the PROMs identified in phase 1 based 
on available information regarding the development 
and psychometric validation of the measures, additional 
publications were accessed via a PROM- specific search 
using Ovid, bibliographic searches and information 
provided by the PROM developers (either online or 
on request). Information about the development and 
psychometric validation was extracted and compared 
across the measures. Only PROMs where information 
on the development and validation history was available 
via an accessible full- text publication were chosen for 
the review. The properties of the PROMs were assessed 
against the FDA guidance for PROMs submitted as a clin-
ical endpoint for drug approval to support a labelling 
claim (online supplementary table S1).12 Information 
related to the use of modern psychometric techniques, 
such as Rasch analysis, was also reviewed where available. 
Rasch models convert ordinal scores into linear, interval- 
level data allowing for easier interpretation, presenting 
both item difficulty and respondent ability on a common 
scale. Further evaluation of the face validity, including 
examination of the item wording and missing concepts, 
was undertaken for PROMs that satisfied most of the 
psychometric assessment criteria.
Table 1 Search strings used in the targeted literature search
Search strings used in the targeted literature search
Patient- reported 
outcomes and 
quality of life
(“quality of life” or “quality- of- life” or QoL or disability or “patient reported outcome*” or “patient- reported 
outcome*” or PRO or “Quality adjusted life year*” or QALY or “Quality- adjusted life year*” or ((activit* adj2 
daily adj2 living) or prefer* or satisfact* or questionnaire or scale or score) or (burden adj5 (societ* or parent* 
or caregiver or humanistic))).mp.
Disease presbyo*.mp.
 o
n
 July 20, 2020 by guest. Protected by copyright.
http://bmjophth.bmj.com/
BM
J O
pen O
phth: first published as 10.1136/bmjophth-2020-000453 on 12 July 2020. Downloaded from 
3Sharma G, et al. BMJ Open Ophth 2020;5:e000453. doi:10.1136/bmjophth-2020-000453
Open access
RESULTS
A total of 703 unique records were identified from 
the literature search during the first round of abstract 
screening, and 120 were selected for full- text review 
(figure 1). Using  ClinicalTrials. gov, a total of 121 clinical 
studies in presbyopia were identified, of which only 21 
mentioned a PROM used to support either a primary 
or secondary endpoint. Seventeen studies with varied 
study designs and sample sizes ranging from 26 to 7890 
participants were found to meet the inclusion criteria for 
full- text review (online supplementary table S2).
In total, 13 PROMs designed to assess vision outcomes 
(including symptoms and/or HRQoL impact) of pres-
byopia or similar vision conditions were identified. Of 
the 13 measures, only one was presbyopia- specific; 11 
were generic eye disease measures used across a range 
of patient groups, including those with refractive correc-
tion (refractive surgery, spectacles and contact lenses) 
and cataracts; and one was a numeric rating scale (NRS) 
assessing overall vision satisfaction and ocular comfort. 
Based on the relevance of content (excluding PROMs 
measuring the effect of dry eye from contact lens use and 
NRS), nine PROMs were deemed suitable for further 
assessment of psychometric properties (table 2). The 
nine- item version of the National Eye Institute Visual 
Function Questionnaire (NEI VFQ-9) is an abbreviated 
version of NEI VFQ-25 and so was not counted separately 
within the nine PROMs identified.
Phase 2 searches were conducted to evaluate and 
compare the psychometric properties of the nine PROMs 
meeting the inclusion criteria from phase 1. PROM- 
specific Ovid searches identified 116 abstracts. Of these 
116 abstracts, 20 had been identified in the phase 1 
searches, 32 were not relevant and the remaining were 
selected for full- text review, of which 23 were included in 
the final review. Information related to the psychometric 
properties of these nine PROMs is presented in table 3.
Content validity
Although patient input was sought in the development 
of most PROMs reviewed, individuals with presbyopia 
were only involved in the item generation process of six 
PROMs: Near Activity Visual Questionnaire (NAVQ), 
National Eye Institute Visual Function Questionnaire 
(NEI VFQ-25), Quality of Vision (QoV), National Eye 
Institute Refractive Error Quality of Life Instrument-42 
(NEI RQL-42), Freedom From Glasses Value Scale 
(FGVS), and Refractive Status And Vision Profile (RSVP). 
While the NAVQ was the only presbyopia- specific PROM 
identified, it should be noted that individuals with 
pseudophakic presbyopia were included in the NAVQ 
development along with individuals with phakic pres-
byopia.14 15 The FGVS16 included individuals diagnosed 
with cataracts or presbyopia who had undergone IOL 
implantation surgery. Refractive error focus groups were 
used to derive items for the NEI RQL-4217 and RSVP,18 
whereas content for the NEI VFQ-2519 20 was informed 
by conducting 26 condition- specific focus groups to 
meet its intended objective of evaluating vision- related 
quality of life across several common eye conditions, 
including cataracts, age- related macular degeneration, 
diabetic retinopathy and glaucoma. Participants involved 
in the item refinement procedure of the QoV21 included 
individuals with and without refractive correction. The 
remaining three PROMs, Catquest- 9SF, Visual Function 
Index (VF-14) and Cataract TyPE Spec, were developed 
with input from individuals with cataract only.22–24
Reliability
The internal consistency of the NAVQ met the accept-
ability threshold of >0.70,14 as did the near vision subscales 
of the NEI VFQ-25, NEI RQL-42 and Cataract TyPE Spec 
(ranging from 0.85 to 0.95).24–26 While high internal 
consistency for the NAVQ (0.945) and Cataract TyPE 
Spec (0.94) indicates that the items are highly correlated 
Figure 1 Flow chart illustrating the study selection process. PRO, patient- reported outcome.
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Table 2 Patient- reported outcome measures in presbyopia considered for evaluation of psychometric characteristics
Patient- reported 
outcome measures Objective
Number of items and available 
domain scores Response options Recall period
Near Activity Visual 
Questionnaire
To assess near- 
visual function 
and satisfaction to 
complement visual 
function evaluations of 
presbyopic corrections.
11 items relating to domains:
 ► Near- vision tasks (10 
items).
 ► Overall satisfaction with 
near vision (1 item).
 ► 4- point verbal descriptor 
scale ranging from ‘no 
difficulty’ to ‘extreme 
difficulty’, along with 
option of ‘N/A or stopped 
for non- visual reasons’.
 ► 5- point verbal descriptor 
scale ranging from 
‘completely satisfied’ to 
‘completely dissatisfied’.
None specified.
National Eye Institute 
Visual Function 
Questionnaire-9
To measure the 
influence of visual 
impairment on quality 
of life.
Abbreviated version of NEI 
VFQ-25 with 9 items in 7 
domains:
 ► General vision.
 ► Well- being/mental health.
 ► Near vision.
 ► Distance vision.
 ► Driving.
 ► Role limitation.
 ► Peripheral vision.
 ► 5- point to 6- point 
verbal descriptor scales 
with variable response 
options.
Present time 
and in general.
National Eye Institute 
Visual Function 
Questionnaire-25
(NEI VFQ-25)
To measure the 
influence of visual 
impairment on quality 
of life.
25 (+1) items in 11 domains:
 ► Global vision rating (1 
item).
 ► Difficulty with near- vision 
activities (3 items).
 ► Difficulty with distance 
vision activities (3 items).
 ► Limitations in social 
functioning due to vision (2 
items).
 ► Role limitations due to 
vision (2 items).
 ► Dependency to others due 
to vision (3 items).
 ► Mental health symptoms 
due to vision (4 items).
 ► Driving difficulties (3 
items).
 ► Limitations with peripheral 
vision (1 item).
 ► Colour vision (1 item).
 ► Ocular pain (2 items).
 ► General health (1 item).
 ► Yes/no.
 ► 3- point to 6- point verbal 
descriptor scales.
Present time 
and in general.
Quality of Vision To measure outcome 
of refractive correction 
and cataract surgery.
30 items made up of 10 
symptoms each assessed in 
3 dimensions:
 ► Frequency.
 ► Severity.
 ► Bothersome.
 ► 4- point verbal descriptor 
scale.
Past week.
Visual Function Index To measure functional 
impairment caused by 
cataract.
18 items in 1 domain:
 ►  Visual impairment.
 ► Yes/no.
 ► 4- point verbal descriptor 
scale.
Currently.
Continued
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Patient- reported 
outcome measures Objective
Number of items and available 
domain scores Response options Recall period
Cataract TyPE Spec To measure outcomes 
of cataract extraction.
12 items assessing visual 
functioning in 5 domains:
 ► Distance vision.
 ► Near vision.
 ► Daytime driving.
 ► Night- time driving.
 ► Glare.
 ► 5- point verbal descriptor 
scale ranging from ‘totally 
disabled’ to ‘not at all’.
Present time.
Catquest- 9SF To measure the benefit 
of cataract surgery.
9 items in 2 domains:
 ► Disability (7 items).
 ► Global evaluation (2 items).
 ► 4- point verbal descriptor 
scale ranging from ‘very 
great difficulty’ to ‘no 
difficulty’ for 6 items, and 
from ‘very dissatisfied’ to 
‘very satisfied’ for 1 item.
Past 4 weeks.
National Eye Institute 
Refractive Error Quality 
of Life Instrument-42
To assess the impact of 
refractive error and its 
correction on day- to- 
day life.
42 items in 13 domains:
 ► Clarity of vision (4 items).
 ► Expectations (2 items).
 ► Near vision (4 items).
 ► Far vision (5 items).
 ► Diurnal fluctuations (2 
items).
 ► Activity limitations (4 
items).
 ► Glare (2 items).
 ► Symptoms (7 items).
 ► Dependence on correction 
(4 items).
 ► Worry (2 items).
 ► Suboptimal correction (2 
items).
 ► Appearance (3 items).
 ► Satisfaction with 
correction (1 item).
 ►  Yes/no.
 ►  3- point to 6- point 
verbal descriptor scale.
Depending on 
the items (At 
this time, The 
last 4 weeks, In 
general, Now, 
…).
Freedom From Glasses 
Value Scale
To assess the added 
value of complete 
independence from 
spectacles after 
multifocal intraocular 
lens surgery.
20 items with 17 items 
grouped under 2 domains:
 ► Global evaluation.
 ► Advantages.
 ► 5- point verbal descriptor 
scale ranging from ‘much 
better’ to ‘much worse’, 
‘very positive’ to ‘very 
negative’, ‘no, not at 
all’ to ‘yes, absolutely’, 
‘totally agree’ to ‘totally 
disagree’, or ‘definitely 
better without glasses’ 
to ‘definitely better with 
glasses’.
Present time.
Refractive Status and 
Vision Profile
For the measurement 
of patient- reported 
outcomes of refractive 
surgery and other 
treatments for 
refractive error.
42 items in 8 domains:
 ► Concern (6 items).
 ► Expectations (2 items).
 ► Physical/social functioning 
(11 items).
 ► Driving (3 items).
 ► Symptoms (5 items).
 ► Optical problems (5 items).
 ► Glare (3 items).
 ► Problems with corrective 
lenses (7 items).
 ► 5- point, 7- point and 
11- point verbal descriptor 
scales with variable 
response options.
During the past 
month.
Table 2 Continued
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and therefore measure the common concept of near 
vision, such high alpha coefficients suggest there may 
be some level of redundancy and that item reduction 
may be possible. Acceptable test–retest reliability was 
found for the NAVQ and near vision subscales of the NEI 
VFQ-25 and NEI RQL-42 (intraclass correlation coeffi-
cient ranging from 0.72 to 0.91), although the same was 
not reported for TyPE Spec. Among other measures that 
do not include a separate near- vision dimension, the 
internal consistency was found to be acceptable (>0.70) 
for FGVS, QoV and RSVP, whereas the test–retest reli-
ability was strong for QoV (>0.70), was modest in the 
case of RSVP (intraclass correlation of 0.66) and was not 
reported for FGVS and NEI VFQ-9.18 21 27 28 As the values 
of reliability for Catquest- 9SF, VF-14 and Cataract TyPE 
Spec were not reported specifically for individuals with 
presbyopia, these were not considered in the analysis.
Construct validity
The assessment of convergent validity showed that the 
NAVQ demonstrated moderate correlations with near 
visual acuity (Pearson’s correlation coefficient (r)=0.32) 
and critical print size (r=0.27), which provided evidence 
of convergent validity.14 Strong correlations (r=0.65–0.70) 
were observed between Early Treatment Diabetic Reti-
nopathy Study visual acuity and NEI VFQ-25 subscales of 
near vision, distance vision and general vision.25 In the 
case of the NEI RQL-42, there was a significant associ-
ation between most of the NEI RQL-42 subscales and 
the refractive error in both better- seeing and worse- 
seeing eyes.26 For the QoV, moderate correlations were 
observed between logMAR visual acuity and the three 
QoV subscales (frequency scale r=0.72, severity scale 
r=0.64 and bothersome scale r=0.35).21 29 No evidence of 
the FGVS correlating with objective clinical parameters 
or subjective measures of visual function was reported.30 
RSVP scores were moderately associated with patient 
satisfaction (r=−0.41) and rating of vision (r=−0.42).31
Discriminant validity for the NAVQ was also supported 
by the high area under the receiver operator charac-
teristic curve (0.91), a Rasch separation index of 2.92, 
and an overall good fit to the Rasch model with negli-
gible ceiling and floor effects.14 The NAVQ scores also 
discriminated between individuals with different kinds 
of correction, such as IOL, contact lenses and varifocal 
spectacles, supporting known groups validity. In the case 
of the NEI VFQ-25, the near- vision and distance- vision 
scores significantly discriminated between participants 
in the reference group (better vision) and those with 
poor vision.25 Although the psychometric performance 
of the NEI VFQ-25 based on analysis using classic test 
theory has been shown to be adequate, analyses using 
Rasch validation methodology have demonstrated 
performance limitation in the near vision subscale and 
general design of the NEI VFQ-25 structure, including a 
substantial ceiling effect.32–34 Scores of the NEI RQL-42 
differed significantly for participants in subgroups 
based on refractive error correction (no correction; 
postsurgery—no correction; glasses; multifocal glasses; 
contact lenses).26 In a Rasch validation study, the NEI 
RQL-42 near vision subscale demonstrated poor discrim-
inative ability as suggested by a person separation index 
of 0.71, which was below the acceptable threshold of 
2.0.35 For the QoV, discriminant ability of the scores was 
demonstrated by acceptable value of person separation 
indexes: 2.08, 2.10 and 2.01 for frequency, severity and 
bothersome scales, respectively.21 29 FGVS score suggested 
discrimination between individuals wearing glasses after 
surgery and those who gained spectacle independence.30 
RSVP scores were shown to distinguish among individ-
uals based on the degree of refractive error. However, 
the Rasch analysis revealed several redundant and 
misfitting items and poor item to person targeting that 
could diminish its discriminative ability.31 The construct 
validity of the remaining measures was not evaluated in a 
presbyopia- specific patient sample nor in a diverse group 
that included a subset of individuals with presbyopia.22–24
Responsiveness
In a randomised, controlled, cross- over trial assessing 
performance of a commercially available contact lens, 
Biofinity users demonstrated significantly greater 
improvements in NAVQ scores compared with OASYS 
contact lens users (p=0.047).36 Gundersen and Potvin37 
reported that QoV scores of frequency, severity and 
degree to which the symptoms were bothersome were 
more sensitive than when using the NEI VFQ-25 in 
detecting between multifocal and monofocal IOLs. 
Furthermore, a cross- over study comparing two pres-
byopic soft contact lens modalities showed that, out of 
13, only the 3 subscales of clarity, vision and appearance 
showed significant improvements in scores compared 
with the habitual correction method on the NEI RQL-42 
scale.38 Gierek- Ciaciura et al39 reported an improvement 
in VF-14 scores for 83% of the individuals after implanta-
tion of multifocal IOLs, although there was no significant 
difference in postoperative scores between individuals 
with different IOLs. Following the bilateral Laser Ante-
rior Ciliary Excision (LaserACE) procedure, a significant 
change in scores was registered on Catquest- 9SF from 
a mean patient satisfaction score of −1.00 to 0.33 after 
surgery (p=0.000016).40 Responder definition or minimal 
important difference thresholds were not reported for 
any of the reviewed questionnaires in individuals with 
presbyopia.
Critical evaluation of the NAVQ
As the NAVQ was the only disease- specific measure iden-
tified at the time of literature review, further critical 
assessment of its face validity was undertaken (figure 2). 
It was concluded that the language used in the instruc-
tions could be interpreted differently by respondents who 
use contact lenses instead of reading spectacles. Further-
more, the absence of a recall period mentioned in the 
instructions could lead to participants using different 
timeframes for recollection.
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Some of the issues identified with the content included 
use of examples of differing difficulty level in the same 
item (items 1, 5, 6 and 7); use of examples not relevant 
to modern times (such as telephone directories, postal 
electricity bills and letters); and examples measuring 
concepts other than near- vision ability (such as writing, 
playing card games and gardening) that assess manual 
dexterity and may lead to spurious scores. In addition, 
more relevant examples assessing ease of typing on a 
smartphone or tablet, reading on an electronic device 
(such as a smartphone, tablet or computer screen) and 
impact of lighting conditions on performing routine 
activities were missing from the items.
DISCUSSION
This literature review identified PROMs developed for 
use in individuals with presbyopia and compared their 
properties in the context of regulatory requirements for 
supporting product label claims.12 Of the nine unique 
measures that were evaluated, only NAVQ was found to 
be developed to measure difficulties in near- vision func-
tion specifically in individuals with presbyopia. The other 
PROMs were found to have limitations related to lack of 
focus on presbyopia and insufficient evidence to support 
strong psychometric properties using modern psychomet-
rics. Modern psychometric methods based on the item 
response theory, such as the Rasch measurement theory, 
provide a robust approach to examine validity and to 
help overcome two key limitations associated with tradi-
tional validation methods based on classic test theory: 
(1) scores are sample- dependent and scale- dependent; 
and (2) SE of measurement around individual subjects’ 
scores is assumed to be a constant value regardless of the 
person’s location on the range of a scale.41 42
While the NAVQ has undergone rigorous psychometric 
analysis and was developed with input from individuals 
with presbyopia, its validation study was performed in 
a sample of individuals with pseudophakic and phakic 
presbyopia, and therefore the results may not be gener-
alisable specifically to phakic presbyopia. Face validity 
analyses revealed the requirement for rewording the 
measure instructions, including a short recall period of 
1 week; reassessment of the relevance of examples; and 
replacement of irrelevant examples with others more 
applicable in present times.
As per FDA’s PRO guidance, examples of modifica-
tions to the original measure that alter responses of 
participants to the same set of questions and therefore 
require qualitative evidence to establish content validity 
include (1) making changes in the order of items, item 
wording, response options or recall period or deleting 
portions of a questionnaire; (2) using the questionnaire 
in a different setting, population or condition from the 
one for which it was originally developed; (3) changing 
instructions or the placement of instructions within the 
PROM; (4) switching mode of administration from paper 
to electronic format; and (5) changing the timing of, or 
procedures for, PROM administration within the clinic 
visit.12 Thus, based on the proposed modifications to the 
NAVQ, a qualitative study confirming the content validity 
and conceptual framework of the revised measure along 
with evidence generated in the context of a well- designed 
trial to support its psychometric properties, both in the 
targeted population of interest, would be necessary for 
the NAVQ to be qualified as a fit- for- purpose measure for 
supporting product labelling claims.
Although this literature review was confined to assessing 
PROMs used in presbyopia studies, it complements 
Figure 2 Near Activity Visual Questionnaire.
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findings of a review by Kandel et al,43 which also identified 
the NAVQ as one of the superior quality questionnaires 
for measuring refractive surgery outcomes related to 
activity limitations. With regard to the limitations, it is 
possible that some relevant literature may have been 
missed due to restrictions of the literature search to 
only a few selected databases, although a bibliographic 
search was also performed to ensure identification of all 
relevant PROMs in presbyopia. Furthermore, the prop-
erties of the culturally adapted versions of the PROMs 
were not assessed, and it is possible that some of the 
identified measures might have performed better in a 
non- English- speaking population. However, such data 
would be unlikely to change the conclusions here, as 
NAVQ is the only presbyopia- specific measure that has 
the potential to support product label claims, although 
with further modification. Given the lack of availability 
of a conceptual model based on patient and clini-
cian input, the final selection of PROMs identified for 
detailed review was not informed by a concept- mapping 
exercise. The results of a recently conducted qualitative 
study in phakic presbyopes and healthcare practitioners 
to develop a conceptual model for the NAVQ modifica-
tion will be reported in a future publication. Finally, it 
is also acknowledged that this literature review did not 
meet the criteria to be considered as a ‘systematic review’. 
However, the authors believe that the approach was suffi-
ciently structured and rigorous (eg, through the use of 
search terms and inclusion criteria) and that ‘systematic’ 
literature review methods are not typically judged neces-
sary or appropriate to identify and evaluate adequately 
PROMS.
CONCLUSION
No single PROM fully adhered to the quality standards 
detailed in the US FDA Guidance for Industry on Patient- 
Reported Outcome Measures (2009), which represents 
best practice methods for PROMs. The NAVQ has the 
most potential to support trial endpoints related to 
changes in near- vision functioning associated with presby-
opia, but with modification. Further research is ongoing 
to confirm the content validity and psychometric validity 
of a revised NAVQ in this specific population.
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